NEWS HIGHLIGHTS RELATED TO FLOVENT ROTADISKMedia Articles Related to Flovent Rotadisk (Fluticasone Inhalation)
Health Tip: Controlling Asthma (HealthDay)
Source: Y! Health News Search RSS Feed [2009.07.02]
HealthDay - (HealthDay News) -- Medication used to control asthma may be
used every day, without the fear of becoming addicted, the American
Academy of Family Physicians says.
Scientists Receive £4.3 Million For Pioneering Asthma And Allergy-Prevention Research, London
Source: Allergy News From Medical News Today [2009.06.30]
Researchers at St George's, University of London have been awarded £4.3 million by the Wellcome Trust for the development of a unique new class of drugs to target the root cause of asthma and allergies. The new Allergen Delivery Inhibitors may be superior to existing medicines, which mainly relieve symptoms. The research team, led by Professor Clive Robinson, has identified novel, drug-like chemical compounds that combat asthma and allergic diseases of the nose, eyes and skin.
Many Adults With Asthma Are Skipping Flu Shots
Source: MedicineNet Asthma Specialty [2009.06.29]
Title: Many Adults With Asthma Are Skipping Flu Shots
Category: Health News
Created: 6/27/2009 7:00:00 AM
Last Editorial Review: 6/29/2009
ATS, ERS Jointly Issue Asthma Assessment Guidelines
Source: Respiratory / Asthma News From Medical News Today [2009.06.26]
The American Thoracic Society and the European Respiratory Society have released official standards for clinical trials and practice with respect to the assessment of asthma. The statement appears in the July 1 issue of the American Journal of Respiratory and Critical Care Medicine. "In the past, there has been no standard way of assessing asthma.
Many Adults With Asthma Are Skipping Flu Shots (HealthDay)
Source: Y! Health Asthma News [2009.06.26]
HealthDay - FRIDAY, June 26 (HealthDay News) -- Adults with asthma face a
higher risk of complications if they catch the flu, yet many skip their
annual shots, new research from the U.S. Centers for Disease Control and
Prevention shows.
Published Studies Related to Flovent Rotadisk (Fluticasone Inhalation)
Preemptive use of high-dose fluticasone for virus-induced wheezing in young children. [2009.01.22]
BACKGROUND: Although virus-induced wheezing is common in preschool-age children, optimal management remains elusive. We examined the efficacy and safety of preemptive treatment with high-dose fluticasone in reducing the severity of recurrent virus-induced wheezing in children... CONCLUSIONS: In preschool-age children with moderate-to-severe virus-induced wheezing, preemptive treatment with high-dose fluticasone as compared with placebo reduced the use of rescue oral corticosteroids. Treatment with fluticasone was associated with a smaller gain in height and weight. Given the potential for overuse, this preventive approach should not be adopted in clinical practice until long-term adverse effects are clarified. (ClinicalTrials.gov number, NCT00238927.) 2009 Massachusetts Medical Society
Bronchodilator reversibility, airway eosinophilia and anti-inflammatory effects of inhaled fluticasone in COPD are not related. [2008.11]
BACKGROUND AND OBJECTIVE: Bronchodilator reversibility (BDR) is common in smoking-related COPD, but the airway pathology underlying this has not been described. In particular, it is not known whether BDR is associated with underlying airway eosinophilia and whether BDR is predictive of a better response to inhaled corticosteroid (ICS) treatment... CONCLUSIONS: BDR was not related to any particular inflammatory phenotype or any clinical or anti-inflammatory response to ICS in these subjects with mild to moderate COPD.
Effectiveness of high repeated doses of inhaled budesonide or fluticasone in controlling acute asthma exacerbations in young children. [2008.09]
OBJECTIVE: The role of inhaled corticosteroids in the treatment of acute asthma exacerbations in children is controversial. This study compared the effect of inhaled budesonide and inhaled fluticasone in controlling acute asthma exacerbations in young children at home... CONCLUSION: Acute asthma exacerbations in young children can be effectively controlled at home with the use of high repetitive doses of inhaled budesonide or inhaled fluticasone, initially together with beta(2)-agonists, given at the beginning of the attack, for a period of 4-8 days.
Efficacy and tolerability of salmeterol/fluticasone propionate versus montelukast in childhood asthma: A prospective, randomized, double-blind, double-dummy, parallel-group study. [2008.08]
BACKGROUND: Asthma control remains suboptimal in adults and children worldwide. Inhaled salmeterol/fluticasone propionate combination (SFC) and oral montelukast (MON) are 2 treatments available for childhood asthma. OBJECTIVE: This study, the PEdiatric Asthma Control Evaluation (PEACE), investigated the efficacy and tolerability of SFC compared with MON for the control of persistent asthma in children... CONCLUSIONS: In these children with uncontrolled asthma previously on short-acting beta(2)-agonist monotherapy (% predicted FEV(1) <80%, frequent asthma symptoms and rescue medication use), treatment with SFC was significantly more effective in improving morning PEF and other measures of asthma control and in decreasing exacerbation rates (in a post hoc analysis) than treatment with MON. The 2 drugs were both well tolerated, with similar numbers and types of AEs reported.
Respirable dose delivery of fluticasone propionate from a small valved holding chamber, a compact breath actuated integrated vortex device and a metered dose inhaler. [2008.07]
AIMS: To compare the respirable dose delivery of the hydrofluroalkane fluticasone propionate (HFA-FP) via an optimally prepared Aerochamber Plus spacer (AP), via a Synchro-Breathe (SB) device, and pMDI Evohaler (EH)... CONCLUSIONS: The use of an optimally prepared AP spacer and breath actuated SB device, when compared with pMDI, significantly increased the respirable dose of HFA-FP.
Clinical Trials Related to Flovent Rotadisk (Fluticasone Inhalation)
A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg Twice Daily To Fluticasone Propionate (FLOVENT) DISKUS 250 Mcg Twice Daily In Symptomatic Patients With Asthma [Active, not recruiting]
This purpose of this study is to show the superiority and long term safety and efficacy of
adding a long acting beta agonist (salmeterol) to constant dose of an inhaled corticosteroid
(fluticasone propionate) in symptomatic subjects with asthma. The 12-month assessment of
asthma control will provide key information on the efficacy and safety of the combination
therapy. The safety measure will be an assessment of adverse events
A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg BID To Fluticasone Propionate (FLOVENT) DISKUS 250 Mcg BID In Symptomatic Subjects With Asthma [Active, not recruiting]
This purpose of this study is to show the superiority and long term safety and efficacy of
adding a long acting beta agonist (salmeterol) to constant dose of an inhaled corticosteroid
(fluticasone propionate) in symptomatic subjects with asthma. The 12-month assessment of
asthma control will provide key information on the efficacy and safety of the combination
therapy. The safety measure will be an assessment of adverse events
Comparison of Esomeprazole to Aerosolized, Swallowed Fluticasone for Eosinophilic Esophagitis [Completed]
Eosinophilic esophagitis (EE) is a recently recognized entity. It has been thought to be
related to both allergies and acid reflux. There have been reports that both swallowed,
aerosolized steroids and proton pump inhibitors have been effective treatments. The
researchers propose to directly compare the efficacy of aerosolized fluticasone to
esomeprazole in the treatment of eosinophilic esophagitis. The hypothesis is that
aerosolized fluticasone (Flovent) will be more effective in relieving symptoms of EE than
esomeprazole (Nexium) treatment. Patients will undergo endoscopy, pH monitoring and manometry
for diagnosis. Following diagnosis of EE by pathology (biopsy of esophagus), patients will
be randomized to esomeprazole or swallowed fluticasone for 8 weeks. At the end of 8 weeks,
subjects will be asked to repeat upper endoscopy with biopsies. Three questionnaires
(dysphagia, gastroesophageal reflux disease [GERD], and allergy) will be completed by the
patient at the first endoscopy and at the end endoscopy. The primary objective is to measure
change in eosinophil infiltration of the esophagus in response to treatment of allergy
(swallowed fluticasone) versus treatment for reflux (esomeprazole) in EE patients.
Repeat Dose Study of Fluticasone Propionate/Salmeterol Versus Fluticasone Propionate + Salmeterol In Asthmatics [Completed]
A new formulation of Fluticasone propionate/Salmeterol comparing a lower dose of fluticasone
propionate and salmeterol was compared with concurrent administration of fluticasone
propionate and salmeterol. Administration occurred over 14 days and tolerability, PK
(pharmacokinetic) and PD (pharmacodynamic) measurements were performed.
A Study Comparing Swallowed Flovent and Placebo in Patients With Eosinophilic Disorders [Active, not recruiting]
The purpose of this study is assessing the efficacy of swallowed Flovent® vs. placebo for the
treatment of eosinophilic esophagitis (EE).
|
